BR112012025558A2 - tratamento para a ataxia-telangiectasia - Google Patents
tratamento para a ataxia-telangiectasiaInfo
- Publication number
- BR112012025558A2 BR112012025558A2 BR112012025558A BR112012025558A BR112012025558A2 BR 112012025558 A2 BR112012025558 A2 BR 112012025558A2 BR 112012025558 A BR112012025558 A BR 112012025558A BR 112012025558 A BR112012025558 A BR 112012025558A BR 112012025558 A2 BR112012025558 A2 BR 112012025558A2
- Authority
- BR
- Brazil
- Prior art keywords
- telangiectasia
- ataxia
- treatment
- tocotrienol
- ataxiatelangiectasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
tratamento para a ataxiatelangiectasia a presente invenção refere-se a métodos para a tratar a ataxiatelangiectasia (a-t) ou uma desordem semelhante à ataxia-telangiectasia (atld) com compostos, tais como tocotrienol quinonas e tocotrienol hidroquinonas, incluindo o alfa-tocotrienol quinona, a fim de aliviar os sintomas da doença
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34190810P | 2010-04-06 | 2010-04-06 | |
PCT/US2011/031133 WO2011126998A1 (en) | 2010-04-06 | 2011-04-04 | Treatment of ataxia telangiectasia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012025558A2 true BR112012025558A2 (pt) | 2016-06-28 |
Family
ID=44763239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012025558A BR112012025558A2 (pt) | 2010-04-06 | 2011-04-04 | tratamento para a ataxia-telangiectasia |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130116336A1 (pt) |
EP (1) | EP2555765A4 (pt) |
JP (1) | JP2013523816A (pt) |
AU (1) | AU2011238525A1 (pt) |
BR (1) | BR112012025558A2 (pt) |
CA (1) | CA2795726A1 (pt) |
EA (1) | EA201201374A1 (pt) |
WO (1) | WO2011126998A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2583087C (en) | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
PL1888059T3 (pl) * | 2005-06-01 | 2015-06-30 | Bioelectron Tech Corp | Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
EP2220030B1 (en) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体 |
WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
MX2011002318A (es) | 2008-09-10 | 2011-05-10 | Edison Pharmaceuticals Inc | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
WO2010045220A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
PT2963006T (pt) | 2008-10-28 | 2018-12-14 | Bioelectron Tech Corp | Composição contendo alfa-tocotrienol quinona e seus intermediários |
EP2424495B1 (en) | 2009-04-28 | 2018-01-17 | Bioelectron Technology Corporation | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
SI2470168T1 (en) * | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
SG10201801321XA (en) * | 2010-04-27 | 2018-04-27 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
CN104582700B (zh) | 2012-11-13 | 2021-01-05 | 因维克特斯生物技术有限公司 | 生育三烯酚的经粘膜递送 |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
PT3233786T (pt) | 2014-12-16 | 2022-05-06 | Ptc Therapeutics Inc | Formas polimórficas e amorfas de (r)-2-hidroxi-2-metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida |
WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
EP3866772B1 (en) | 2018-10-17 | 2023-10-11 | PTC Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders |
EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2583087C (en) * | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
WO2006053010A2 (en) * | 2004-11-09 | 2006-05-18 | Hill's Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
PL1888059T3 (pl) * | 2005-06-01 | 2015-06-30 | Bioelectron Tech Corp | Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych |
JP2011513420A (ja) * | 2008-03-05 | 2011-04-28 | エジソン ファーマシューティカルズ, インコーポレイテッド | レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置 |
MX2011002318A (es) * | 2008-09-10 | 2011-05-10 | Edison Pharmaceuticals Inc | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
JP2012525397A (ja) * | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ, インコーポレイテッド | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
WO2011082355A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
SG10201801321XA (en) * | 2010-04-27 | 2018-04-27 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-04 BR BR112012025558A patent/BR112012025558A2/pt not_active IP Right Cessation
- 2011-04-04 AU AU2011238525A patent/AU2011238525A1/en not_active Abandoned
- 2011-04-04 EA EA201201374A patent/EA201201374A1/ru unknown
- 2011-04-04 US US13/639,494 patent/US20130116336A1/en not_active Abandoned
- 2011-04-04 CA CA2795726A patent/CA2795726A1/en not_active Abandoned
- 2011-04-04 WO PCT/US2011/031133 patent/WO2011126998A1/en active Application Filing
- 2011-04-04 JP JP2013503818A patent/JP2013523816A/ja not_active Ceased
- 2011-04-04 EP EP20110766566 patent/EP2555765A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2555765A4 (en) | 2013-08-14 |
EP2555765A1 (en) | 2013-02-13 |
JP2013523816A (ja) | 2013-06-17 |
US20130116336A1 (en) | 2013-05-09 |
WO2011126998A1 (en) | 2011-10-13 |
CA2795726A1 (en) | 2011-10-13 |
AU2011238525A1 (en) | 2012-11-08 |
EA201201374A1 (ru) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012025558A2 (pt) | tratamento para a ataxia-telangiectasia | |
BR112014024672A8 (pt) | Composições farmacêuticas para terapia de combinação | |
EA202091568A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
BR112014004859A2 (pt) | preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmas | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
BR112016017690A2 (pt) | Tratamentos para acne resistente | |
GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
BR112015010146A2 (pt) | sílica precipitada tratada com calor | |
BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112015024926A2 (pt) | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe | |
BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112013016789A2 (pt) | tratamento da dor associado ao deslocamento do endométrio basal | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
BR112015017775A2 (pt) | enzima cistationina beta-sintase para o tratamento de homocistinúria | |
BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina | |
BR112017021191A2 (pt) | um extrato de indigo naturalis e um processo para preparar o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |